This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2005 Remove Leads Remove Pharmacology Related Topics
Pharmaceutical research Food and Drug Administration Safety Side effects FDA Healthcare Physicians Networking Patients Food More Related Topics >
article thumbnail

The future of medical cannabis development in Europe

European Pharmaceutical Review

JULY 13, 2023

This could lead to significant research waste. This will lead to a higher proportion of these medicines becoming licensed, benefitting a larger number of patients. He leads the pre-clinical and clinical medical cannabis research programmes in Europe and is responsible for the cannabis clinic rollout across the continent.

Medical 86
Medical Food and Drug Administration Pharmacology Medicine 86
article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

SEPTEMBER 22, 2023

Targeting toxic species of Abeta, such as multimers (with aducanumab and lecanemab) or pyroglutamate Abeta3-42 (with donanemab), induced significant removal of Abeta plaque load in the brains of Alzheimer’s patients, leading to the delay in cognitive decline. Treatment with the mAbs delayed cognitive decline by 2.6 months for lecanemab and 5.5

Food and Drug Administration 78
Food and Drug Administration Safety Patients Leads 78
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 8,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024